Companies › Spinogenix
1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SPG302 synthetic small molecule | – | Phase 2 | Alzheimer Disease; Schizophrenia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06427668 | SPG302 | Phase 2 | Alzheimer Disease | Neurology | Dec 2025 |
| NCT06442462 | SPG302 | Phase 2 | Schizophrenia | Psychiatry | Mar 2026 |
No annotated target.
–
Shanghai Auzone Biological Technology Reunion Neuroscience TrueBinding Noema Pharma MapLight Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.